

RYTHMO

Le séminaire de rythmologie pratique
dédié aux cardiologues

7^{ÈME} ÉDITION

SAMEDI 29 NOVEMBRE 2025

PULLMAN LYON

44 Bd Marius Vivier Merle
69003 Lyon

Le rôle clef de l'IA pour aider
dans l'ablation de la FA
persistante

Dr Julien SEITZ




Coordinateur de l'unité de
Rythmologie interventionnelle
Hôpital Saint Joseph-Marseille

Disclosures

Speaker Fees: Biosense Webster, Abbott

Co-founder & shareholder of Volta Medical

Ablation de la FA paroxystique par déconnection des VPs: un gold standard





Comment doit-on ablater les FA persistantes ?

Malgré de nombreuses expériences monocentriques
prometteuses avec différentes approches ...



STAR AFII: Pas de bénéfice à faire plus que l'isolation des VPs ("less is more")



Approche anatomique ?

Approche anatomique: focus sur les grands essais randomisés internationaux


No large RCT-evidence of a superiority in comparison to standard of care

STAR AF II trial **Negative**


598 patients, 12 countries, 48 centers

Persistent AF: 7 days - 3 years

PVI vs PVI + lines



167 min



223 min

Blind & stringent Follow up


18 mo-Freedom from AF/AT multiple procedures: 61% Vs 48% (p:ns).

CAPLA trial **Negative**


338 patients, 2 countries, 16 centers

Persistent AF: 7 days - 3

PVI vs PVI + PWI




121 min



142 min

Blind & stringent Follow up

12 mo-Freedom from AF/AT multiple procedures: 62% vs 60% (p:ns).



Approche anatomique – Alcoolisation veine de Marshall: essais randomisés académiques nationaux

Alcoolisation veine de Marshall améliore résultats de l'ablation.


Procédures longues et extensives

Sous ou sur traitement

Bénéfice après plusieurs procédures?

Quelle stratégie en cas d'échec?


Freedom from AF/AT, 1 or 2 procedures*



Approche sur mesure ?


Mapping automatique des sources de la FA

CFAE Abbott/BW




Negative RCT
(STAR AF2)

Fibrosis maps MRI




Negative RCT
(DECAAFII)

Fibrosis maps Voltage




3 Negative RCT
(Stable SR2, Supres AF, SCAR AF)
1 controversial (Erase AF)

DF maps




No RCT

Driver maps BW




No RCT

Driver maps Topera




No RCT

Driver maps ECGi




No RCT

Driver maps ACUTUS



No RCT

Driver maps ABLACON




No RCT


**No strong evidence of a superiority in comparison to standard of care
in de novo persistent AF ablation**

Visual EGM-based detection of AF drivers


In the history of EGM-based AF ablation, several targets have been described with promising, but poorly reproducible outcomes.



Nademanee et al. JACC 2004




Takahashi et al. JACC. 2008




Narayan et al. Heart Rhythm 2011



Ganesan et al. Heart Rhythm 2013



Jadidi et al. Circ. EP 2016



Seitz et al. JACC 2017

Spatio-temporal Dispersion

Spatiotemporal dispersion as a strategy for the assessment of AFib



4500 + AF PATIENTS



> 85% PERSISTENT AF PATIENTS



50+ CENTERS IN THE WORLD

DISPERSION STUDIES ANALYSED

37 Scientific publications

3 Randomized trials


8 Prospective studies

2 Retrospective studies

3 Studies on dispersion characteristics

3 Case reviews

18 Abstracts



2 positive RCT in china

This list is not exhaustive. Some studies are ongoing or pending publication and are not listed here.

Dispersion-guided Tailored ablation Vs PVI only


In favor of Dispersion

In favor of PVI

A) AF Recurrence

| Study | logOR | Weight SE (common) | Weight (random) | Odds Ratio IV, Fixed + Random, 95% CI |
|--------------------------------------|---------|--------------------|-----------------|---------------------------------------|
| Melby et al. 2019 | -2.5154 | 1.2740 | 2.4% | 0.08 [0.01; 0.98] |
| Lin et al. 2019 | -1.7327 | 0.9728 | 4.1% | 0.18 [0.03; 1.19] |
| Garcia et al. 2023 | -1.1978 | 0.4283 | 21.2% | 0.30 [0.13; 0.70] |
| Deisenhofer et al. 2025 | -1.1216 | 0.3436 | 33.0% | 0.33 [0.17; 0.64] |
| Hu et al. 2020 | -1.1067 | 0.6873 | 8.2% | 0.33 [0.09; 1.27] |
| Qin et al. 2018 | -0.9822 | 1.0564 | 3.5% | 0.37 [0.05; 2.97] |
| Sakata et al. 2023 | -0.0939 | 0.3754 | 27.6% | 0.91 [0.44; 1.90] |
| Total (common effect, 95% CI) | | 100.0% | | 0.40 [0.27; 0.59] |
| Total (random effect, 95% CI) | | | 100.0% | 0.39 [0.22; 0.69] |
| Prediction interval | | | | [0.17; 0.92] |


Heterogeneity: Tau² = 0.0684; Chi² = 7.94, df = 6 (P = 0.2422); I² = 24.5%



C) ATa Recurrence

| Study | logOR | Weight SE (common) | Weight (random) | Odds Ratio IV, Fixed + Random, 95% CI |
|--------------------------------------|---------|--------------------|-----------------|---------------------------------------|
| Lin et al. 2019 | -1.0569 | 0.5649 | 7.6% | 0.35 [0.11; 1.05] |
| Hu et al. 2020 | -1.0508 | 0.5334 | 8.5% | 0.35 [0.12; 0.99] |
| Melby et al. 2019 | -0.5507 | 0.4069 | 14.6% | 0.58 [0.26; 1.28] |
| Deisenhofer et al. 2025 | -0.0047 | 0.2646 | 34.5% | 1.00 [0.59; 1.67] |
| Garcia et al. 2023 | 0.3797 | 0.4031 | 14.8% | 1.46 [0.66; 3.22] |
| Sakata et al. 2023 | 0.5322 | 0.3669 | 17.9% | 1.70 [0.83; 3.50] |
| Qin et al. 2018 | 0.9822 | 1.0564 | 2.2% | 2.67 [0.34; 21.17] |
| Total (common effect, 95% CI) | | 100.0% | | 0.93 [0.68; 1.25] |
| Total (random effect, 95% CI) | | | 100.0% | 0.86 [0.45; 1.66] |
| Prediction interval | | | | [0.21; 3.62] |

Heterogeneity: Tau² = 0.2712; Chi² = 12.82, df = 6 (P = 0.0460); I² = 53.2%



Ablation of visual spatiotemporal dispersion added to pulmonary vein isolation in persistent atrial fibrillation ^{FREE}

E Franco, C Lozano-Granero, M C Amores Luque, R Matia Frances, A Hernandez-Madrid, J L Zamorano, J Moreno [Author Notes](#)

European Heart Journal, Volume 46, Issue Supplement_1, November 2025, ehaf784.489, <https://doi.org/10.1093/eurheartj/ehaf784.489>

Published: 05 November 2025


385 patients with persistent AF

LS persistent =11%


Structural heart disease =38%

Classical FU (ECG/holters)

SURVIVAL FREE FROM ATRIAL ARRHYTHMIAS (%)




PROGRESSION TO PERMANENT AF (%)




Mais ablation guidée par analyse visuelle des EGM
complexe et peu reproductible

How to automatize complex multiparametric analysis?

Chihuahua or Muffin?




Conventional algorithm:



(Few) Features & Thresholds are decided by engineers. **Rough boundaries.**

Machine learning algorithm:




Thresholds and a potentially high number of features are automatically extracted from data during training. **Accurate boundaries.**

How to automatize complex multiparametric analysis?



Facial recognition



Intra cardiac EGM analysis

A well trained human brain is very powerful to perform complex multiparametric analysis but it is difficult for conventional algorithms.

VX1 (Volta) is an AI-based software that allows for the reproducible detection and ablation of AF drivers


FDA approval

CE Mark



PRIX GALIEN USA

2023
Best start up



Journal of
Cardiovascular
Electrophysiology


Seitz et al. JCE 2022

1. Based on the concept of Dispersion. *Seitz et al. JACC 2017*

Artificial intelligence for individualized treatment of persistent atrial fibrillation: a randomized controlled trial

Deisenhofer et al. Nature medicine 2025

- **374 patients** 
- **51 investigators**
- **26 sites (8 US, 18 EU)** 
- **5 countries** FDA IDE trial




Patient population:


Denovo Persistent AF: 3 months - 5 years

Female = 21% (*pre-specified subgroup*)

Pst AF \geq 6 months = 55% (*pre-specified subgroup*)



12-month Follow-up
Blind & Independent




Tailored AF Perspectives

AI-guided ablation for redo ablations: *The Restart trial*

PVI/PVI+ failure despite isolated PVs: no consensus on ablation strategy*


92 patients, 29 investigators, 20 sites



12-month follow-up:


ECG, Holters 24-hour (24%) minimum, 2 to 7-day (25%), 14 to 30-day (16%) Holter, **cardiac implantable device (26%)**

Freedom from arrhythmia at 12 months




Quality of Life significantly improved

Overall AFEQT score



General health SF-36 score




Hummel et al. Late breaking trial session HRS 2025

*Average results from Schmidt et al. Circ 2024, Sciacca et al. JCE 2022, Weng et al. JCE 2022



Tailored-AF workflow with PFA


Persistent AF > 6 months. Mapping AF Xplorer (circular configuration).




PROCEDURE= 65 MIN
PFA = 8 MIN




AT diagnosis prediction without mapping



Ablation set generation



Dispersion heat maps & mapping in sinus rhythm



CONCLUSIONS

TAILORED-AF: 1st Large-scale rigorous international RCT demonstrating superiority against PVI using a patient-tailored approach

The use of AI for the objective, reproducible and reliable identification of target EGMs seems to have been pivotal.

RESTART: Tailored-AF like approach is also very promising in redo ablations procedure in patients with isolated PVs.



RYTHMO

Le séminaire de rythmologie pratique
dédié aux cardiologues

7^{ÈME} ÉDITION

SAMEDI 29 NOVEMBRE 2025

PULLMAN LYON

44 Bd Marius Vivier Merle
69003 Lyon

Merci de votre attention!

Dr Julien SEITZ

Coordinateur de l'unité de
Rythmologie interventionnelle
Hôpital Saint Joseph-Marseille

“AI could solve some of Humanity's hardest problems. It already has...”

Demis Hassabis, DEEP mind (Nobel Laureate for AlphaFold Project)

...Hopefully we are on the way to solve AFib


Tailored AF questions :

Atrial tachycardias, Dispersion extent, Atrial contraction

Arrhythmia Type After Persistent Atrial Fibrillation Ablation Predicts Success of the Repeat Procedure



Sonia Ammar, MD, Gabriele Hessling, MD, Tilko Reents, MD, Stephanie Fichtner, MD, Jinjin Wu, MD, Pinjun Zhu, MD, Susanne Kathan, Dipl Biol, Heidi Louise Estner, MD, Clemens Jilek, MD, Christof Kolb, MD, Bernhard Haller, Dipl Stat, and Isabel Deisenhofer, MD



Recurrence in AT is associated with a high success rate after repeat ablation

| No. of patients, entering the interval | 0-3 | 3-6 | 6-9 | 9-12 |
|--|-----|-----|-----|------|
| Group 1 | 36 | 22 | 18 | 9 |
| Group 2 | 37 | 15 | 7 | 4 |
| Group 3 | 5 | 5 | 3 | 0 |

Circulation: Arrhythmia and Electrophysiology

Volume 4, Issue 5, October 2011; Pages 609-614

<https://doi.org/10.1161/CIRCEP.111.963256>



Repeat procedure: Majority of AT are typical macro reentries easy to ablate

AT termination by ablation = 100%

The 43 Tailored patients re-ablated for AT


N= 8 pts

100% of Localized AT were diagnosed in regions where **dispersion had previously been detected and partially ablated** during the index procedure.



N=31 pts

93% of Macroreentries were due to **permeable (60%) or incomplete (33%) connection lines** made during the index procedure.







Primo Procedure Repeat procedure – Roof Flutter



Dispersion extent in Tailored AF procedures*

LA : $18 \pm 13.5\%$

RA : $2 \pm 4.8\%$






Dispersion-guided Tailored ablation is adapted on AF substrate and allows for myocardial preservation

*: automated measurements on 3D shells

What about atrial contraction after a "Tailored" workflow?

Transmitral flow in 24 persistent AF patients with "tailored" workflow (abl. ant wall* =100%) in stable SR at 22 ± 10 months.





A wave recovery in 100% of patients (no symptoms)


*Extensive = 47% with ant line = 37%

Tailored-AF workflow with PFA


Persistent AF > 4 months. Mapping AF Xplorer (circular configuration).



PROCEDURE= 83 MIN
PFA = 7 MIN, RF = 25 SEC



Low voltage-guided ablation: focus on RCT data



JACC
Clinical
Electrophysiology

HeartRhythm

- **STABLE SR II** (Yang et al. 2022): multicenter RCT (n=300 pst AF) -> **negative**
- **SCAR AF** (Lepillier et al. 2025): multicenter RCT (n=210 pst AF) -> **negative**
- **SUPRESS AF** (Masuda et al. 2025): multicenter RCT (n=343 pst AF) -> **negative**

nature
medicine

NEJM
Evidence

- **ERASE AF**: multicenter RCT (n=324 pst AF) -> **positive**
Strong limitation: (70%) without low voltage areas in both arms treated by PVI only.

The jury is still out about low voltage-guided ablation


Dispersion-guided ablation Vs Stepwise ablation

Monocentric national academic **positive RCT**

142 pts with persistent AF, LS-Pst AF: 25%, LA 43 mm, LVEF: 61%, CHAD2DS2-VASc: 2

AF termination : **70.4%** vs **10.5%**


B



| | | | | | |
|---------|----|----|----|---|---|
| Group A | 71 | 71 | 33 | 8 | 4 |
| Group B | 71 | 71 | 26 | 6 | 4 |

Multi-centre, prospective randomized comparison of three different substrate ablation strategies for persistent atrial fibrillation

Kaige Li^{1†}, Changhao Xu^{1†}, Xiyao Zhu², Xinhua Wang³, Ping Ye⁴, Weifeng Jiang¹, Shaohui Wu¹, Kai Xu¹, Xiangting Li⁵, Ying Wang⁶, Qidong Zheng⁷, Yanzhe Wang⁸, Lihua Leng⁹, Zengtang Zhang¹⁰, Bing Han¹¹, Yu Zhang¹, Mu Qin^{1*}, and Xu Liu^{1*}




PVI+PWI+Mitral/Marshall*

PVI+Dispersion

PVI+Dispersion+
PWI+Mitral/Marshall*

450 persistent AF patients (LS-pst AF = 50%)
Follow up: ECG/ 48-hrs Holters (M3-6-9-12),
7-days holters if symptoms



* Marshall = 43%